Physician profile
Cassandra E Bray
NPI 1700935897
$8,785.08
in general payments reported to CMS, 2019-2025
44 companies · $21.92 in 2025
The $21.92 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,558 · 2020: $1,647 · 2021: $2,343 · 2022: $2,082 · 2023: $1,134 · 2025: $21.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,343.54 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $788.69 | 2019-2023 | Ubrelvy, Vraylar, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $533.80 | 2019-2023 | Breztri, Farxiga |
| Dexcom, INC. | $525.05 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $462.74 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $391.60 | 2019-2023 | |
| Amarin Pharma, INC. | $383.93 | 2019-2023 | |
| Glaxosmithkline, LLC. | $383.39 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $323.51 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $318.93 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.96 | 2020-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $237.53 | 2021-2023 | |
| Esperion Therapeutics, INC. | $227.18 | 2020-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $217.20 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.